ALEC Alector Inc

Price (delayed)

$6.02

Market cap

$576.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.56

Enterprise value

$539.23M

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system ...

Highlights
The debt has contracted by 10% YoY and by 3.3% from the previous quarter
ALEC's EPS is up by 8% from the previous quarter and by 3.7% YoY
The quick ratio has plunged by 60% YoY and by 20% from the previous quarter
The equity has decreased by 37% YoY and by 17% QoQ

Key stats

What are the main financial stats of ALEC
Market
Shares outstanding
95.75M
Market cap
$576.41M
Enterprise value
$539.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.78
Price to sales (P/S)
5.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.56
Earnings
Revenue
$97.06M
EBIT
-$125.18M
EBITDA
-$116.33M
Free cash flow
-$186.54M
Per share
EPS
-$1.56
Free cash flow per share
-$2.23
Book value per share
$1.59
Revenue per share
$1.16
TBVPS
$7.43
Balance sheet
Total assets
$621.83M
Total liabilities
$487.67M
Debt
$38.92M
Equity
$134.16M
Working capital
$387.86M
Liquidity
Debt to equity
0.29
Current ratio
3.18
Quick ratio
3.09
Net debt/EBITDA
0.32
Margins
EBITDA margin
-119.9%
Gross margin
100%
Net margin
-134.3%
Operating margin
-156.3%
Efficiency
Return on assets
-19%
Return on equity
-77.2%
Return on invested capital
-27.2%
Return on capital employed
-28.2%
Return on sales
-129%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALEC stock price

How has the Alector stock price performed over time
Intraday
-0.99%
1 week
-3.37%
1 month
-13.88%
1 year
-3.37%
YTD
-24.56%
QTD
-24.56%

Financial performance

How have Alector's revenue and profit performed over time
Revenue
$97.06M
Gross profit
$97.06M
Operating income
-$151.74M
Net income
-$130.39M
Gross margin
100%
Net margin
-134.3%
ALEC's operating margin has dropped by 51% year-on-year but it is up by 6% since the previous quarter
The net margin has contracted by 35% YoY but it has grown by 9% from the previous quarter
ALEC's gross profit is down by 27% YoY
The revenue has declined by 27% year-on-year

Growth

What is Alector's growth rate over time

Valuation

What is Alector stock price valuation
P/E
N/A
P/B
3.78
P/S
5.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.56
ALEC's EPS is up by 8% from the previous quarter and by 3.7% YoY
The equity has decreased by 37% YoY and by 17% QoQ
ALEC's P/B is 20% below its 5-year quarterly average of 4.7 but 11% above its last 4 quarters average of 3.4
The stock's price to sales (P/S) is 84% less than its 5-year quarterly average of 33.1 and 3.9% less than its last 4 quarters average of 5.4
The revenue has declined by 27% year-on-year

Efficiency

How efficient is Alector business performance
The return on equity has declined by 48% year-on-year and by 3.2% since the previous quarter
ALEC's ROS is down by 33% YoY but it is up by 9% from the previous quarter
Alector's ROA has decreased by 23% YoY but it has increased by 2.1% from the previous quarter
The return on invested capital has declined by 11% year-on-year

Dividends

What is ALEC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALEC.

Financial health

How did Alector financials performed over time
ALEC's total assets is 28% greater than its total liabilities
The quick ratio has plunged by 60% YoY and by 20% from the previous quarter
Alector's current ratio has plunged by 59% YoY and by 19% from the previous quarter
The debt is 71% less than the equity
The debt to equity is up by 45% year-on-year and by 16% since the previous quarter
The equity has decreased by 37% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.